Results 31 to 40 of about 18,827 (200)

Population Pharmacokinetics of Palbociclib in a Real-World Situation

, 2021
Palbociclib is an oral cyclin-dependent kinase inhibitor that is used in combination with aromatase inhibitors in the treatment of postmenopausal women with metastatic breast cancer.
Audrey Hennequin, Sivia Ilie, Antonin Schmitt, Bernard Royer, Siavoshe Ayati, Didier Mayeur, Sylvain Ladoire, Jean-David Fumet, Isabelle Desmoulins, Courèche Kaderbhaï   +9 more
core   +1 more source

Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor–Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial

, 2021
IMPORTANCE: The cyclin-dependent kinase 4 and 6 inhibitor palbociclib in combination with letrozole has become a standard first-line treatment for patients with endocrine-sensitive, hormone receptor–positive, ERBB2-negative advanced breast cancer ...
Di Cosimo, Serena, Aguirre, Elena, Schneeweiss, Andreas, Sampayo-Cordero, Miguel, Amillano, Kepa, Bellet, Meritxell, Albanell, Joan, Schmid, Peter, Ruíz-Borrego, Manuel, Wheatley, Duncan, Zamora, Pilar, Gavilá, Joaquín, Marmé, Frederik, PARSIFAL Steering Committee and Trial Investigators, Llombart-Cussac, Antonio, Malfettone, Andrea, Dalenc, Florence, Gligorov, Joseph, Gil-Gil, Miguel, Pérez-García, José Manuel, Cortés, Javier, Martínez-de Dueñas, Eduardo   +21 more
core   +2 more sources

Palbociclib Adherence and Persistence in Patients with Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer

Patient Preference and Adherence, 2023
Nicole M Engel-Nitz,1 Mary G Johnson,1 Michael P Johnson,1 Ashley S Cha-Silva,2 Samantha K Kurosky,2 Xianchen Liu2 1Optum, Eden Prairie, MN, 55344, USA; 2Pfizer Inc, New York, NY, 10017, USACorrespondence: Nicole M Engel-Nitz, HEOR | Optum Life Sciences,
Engel-Nitz NM, Johnson MG, Johnson MP, Cha-Silva AS, Kurosky SK, Liu X   +5 more
doaj  

FGFR1 Overexpression Induces Cancer Cell Stemness and Enhanced Akt/Erk-ER Signaling to Promote Palbociclib Resistance in Luminal A Breast Cancer Cells

Cells, 2021
Resistance to CDK4/6 inhibitors (CDKis) is emerging as a clinical challenge. Identification of the factors contributing to CDKi resistance, with mechanistic insight, is of pivotal significance.
Qiong Cheng, Zhikun Ma, Yujie Shi, Amanda B. Parris, Lingfei Kong, Xiaohe Yang   +5 more
doaj   +1 more source

Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER(+)/HER2(−) Breast Cancer [PDF]

, 2021
PURPOSE: To determine (i) the relationship between candidate biomarkers of the antiproliferative (Ki67) response to letrozole and palbociclib alone and combined in ER(+)/HER2(−) breast cancer; and (ii) the pharmacodynamic effect of the agents on the ...
Liu, Y, Pogue-Geile, Katherine, Dowsett, Mitch, Cheang, M, Holcombe, Chris, Turner, Nick, Osborne, C Kent, Turner, N, Jacobs, Samuel A, Rimawi, Mothaffar F., Jacobs, Samuel A., Osborne, CK, Perry, Sophie, Rimawi, Mothaffar F, Swift, Claire, Pogue-Geile, K, Kilburn, Lucy, Dodson, A, PALLET trialists,, Jacobs, SA, Perry, S, Bliss, Judith M., Dowsett, M, Puhalla, S, Dodson, Andrew, Finnigan, M, Martins, V, Rimawi, MF, Kilburn, L, Bliss, Judith M, Bliss, JM, Finnigan, Melanie, Liu, Yuan, Holcombe, C, Puhalla, Shannon, Johnston, Stephen, Swift, C, Johnston, S, Osborne, C. Kent, Martins, Vera, Cheang, Maggie   +40 more
core   +1 more source

Cyclin E1 expression and palbociclib efficacy in previously treated hormone receptor-positive metastatic breast cancer [PDF]

, 2019
PURPOSE: A large-panel gene expression analysis was conducted to identify biomarkers associated with the effectiveness of adding palbociclib to fulvestrant.
Liu, Y, Michiels, SP, Loi, S, Colleoni, M, Harbeck, N, André, F, Zhang, Z, Arnedos, M, Turner, NC, Bayar, MAM, Cristofanilli, M, DeMichele, A, Bartlett, CH, Zhu, Z, Giorgetti, C, Loibl, S   +15 more
core   +2 more sources

The Impact of Real-World Alternative Dosing Strategies of Palbociclib on Progression-Free Survival in Patients with Metastatic Breast Cancer

Current Oncology, 2022
Background: Palbociclib, a cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitor, in combination with letrozole or fulvestrant has been demonstrated to prolong the progression-free survival (PFS) in patients with hormone receptor-positive (HR+), human ...
Fulbert Fu, Jessica Kano, Julia Ma, Mera Guindy   +3 more
doaj   +1 more source

PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy—Safety and Efficacy in Asian Patients

Journal of Global Oncology, 2017
Purpose: To assess efficacy and safety of palbociclib plus fulvestrant in Asians with endocrine therapy–resistant metastatic breast cancer. Patients and Methods: The Palbociclib Ongoing Trials in the Management of Breast Cancer 3 (PALOMA-3) trial, a ...
Hiroji Iwata, Seock-Ah Im, Norikazu Masuda, Young-Hyuck Im, Kenichi Inoue, Yoshiaki Rai, Rikiya Nakamura, Jee Hyun Kim, Justin T. Hoffman, Ke Zhang, Carla Giorgetti, Shrividya Iyer, Patrick T. Schnell, Cynthia Huang Bartlett, Jungsil Ro   +14 more
doaj   +1 more source

Palbociclib treatment alters nucleotide biosynthesis and glutamine dependency in A549 cells

Cancer Cell International, 2020
Background Aberrant activity of cell cycle proteins is one of the key somatic events in non-small cell lung cancer (NSCLC) pathogenesis. In most NSCLC cases, the retinoblastoma protein tumor suppressor (RB) becomes inactivated via constitutive ...
Lindsey R. Conroy, Pawel Lorkiewicz, Liqing He, Xinmin Yin, Xiang Zhang, Shesh N. Rai, Brian F. Clem   +6 more
doaj   +1 more source

Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study

BMC Cancer, 2022
Introduction Approximately 20–33% of all cancer patients are treated with acid-reducing agents (ARAs), most commonly proton pump inhibitors (PPIs), to reduce gastroesophageal reflux disease symptoms.
Kadir Eser, Arif Hakan Önder, Emel Sezer, Timuçin Çil, Ali İnal, Banu Öztürk, Vehbi Erçolak, Berna Bozkurt Duman, Halil Çelik, Tolga Köşeci, Oğuzhan Kesen   +10 more
doaj   +1 more source